Key result
In a systematic review of tuberculous myocarditis cases, 68% of patients responded well to antituberculosis treatment, but the therapy did not appear to prevent sudden cardiac death, which occurred in 31% of cases.
Why the study?
Does antituberculosis drug therapy reduce sudden cardiac death in patients with tuberculous myocarditis?
Systematic Review (n=16)
Does antituberculosis drug therapy reduce sudden cardiac death in patients with tuberculous myocarditis?
Tuberculous myocarditis is a rare but highly fatal condition, particularly in young males, where standard antituberculosis therapy does not appear to prevent sudden cardiac death.
Answers are grounded in this paper and cite their sources.
Standard antituberculosis therapy may not prevent sudden cardiac death in tuberculous myocarditis; leaves open the need for adjunctive strategies in prospective studies.
Tuberculosis is a rare cause of myocarditis. It is however associated with a high mortality when it occurs and is often diagnosed at post-mortem. Tuberculous myocarditis prevalence in males is twice that in females. Most of the reported cases of tuberculous myocarditis are predominantly in immunocompetent patients. Out of the reported fatalities (sudden cardiac deaths), eighty one percent (81%) occur in the 'young' patients (below 45years). Antituberculosis drug therapy does not appear to offer mortality benefit against sudden cardiac deaths.
No takes yet. Share an insight, caveat, or question.
Michira et al. (2015) conducted a systematic review in Tuberculous myocarditis (n=16). Antituberculosis treatment was evaluated on Response to antituberculosis treatment. In a systematic review of tuberculous myocarditis cases, 68% of patients responded well to antituberculosis treatment, but the therapy did not appear to prevent sudden cardiac death, which occurred in 31% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: